These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 14533347

  • 1. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL, Ramos F, Hospenthal DR.
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [Abstract] [Full Text] [Related]

  • 2. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [Abstract] [Full Text] [Related]

  • 3. Pegylated interferons.
    Baker DE.
    Rev Gastroenterol Disord; 2001 Jun; 1(2):87-99. PubMed ID: 12120178
    [Abstract] [Full Text] [Related]

  • 4. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ, Romagosa R, Vincek V.
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract] [Full Text] [Related]

  • 5. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T, Farkas A, Tolvaj G, Horváth G.
    Orv Hetil; 2006 Feb 19; 147(7):321-4. PubMed ID: 17489160
    [Abstract] [Full Text] [Related]

  • 6. Erythema gyratum repens induced by pegylated interferon alfa for chronic hepatitis C.
    Rongioletti F, Fausti V, Parodi A.
    Arch Dermatol; 2012 Oct 19; 148(10):1213-4. PubMed ID: 23069974
    [No Abstract] [Full Text] [Related]

  • 7. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
    Lin J, Lott JP, Amorosa VK, Kovarik CL.
    J Am Acad Dermatol; 2009 May 19; 60(5):882-3. PubMed ID: 19389538
    [No Abstract] [Full Text] [Related]

  • 8. [Thyroid dysfunction in patients with chronic hepatitis C treated with pegylated interferon alpha].
    Montero-Tinnirello J, de la Fuente-Aguado J, Rodríguez-Pecci MS, Fernández-Fernández FJ.
    Rev Clin Esp; 2011 Sep 19; 211(8):436-8. PubMed ID: 21546017
    [No Abstract] [Full Text] [Related]

  • 9. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C.
    Balderramo DC, García O, Colmenero J, Espinosa G, Forns X, Ginès P.
    Dig Liver Dis; 2009 Jul 19; 41(7):e4-7. PubMed ID: 18243078
    [Abstract] [Full Text] [Related]

  • 10. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep 19; 144(38):59. PubMed ID: 12395712
    [No Abstract] [Full Text] [Related]

  • 11. [Sarcoidosis induced by therapy with pegylated interferon alfa-2a].
    Bruch-Gerharz D, Reifenberger J.
    Hautarzt; 2006 Apr 19; 57(4):317-35. PubMed ID: 16523277
    [No Abstract] [Full Text] [Related]

  • 12. Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C.
    Lörke J, Erhardt A, Häussinger D.
    Clin Gastroenterol Hepatol; 2004 Dec 19; 2(12):xx. PubMed ID: 15625645
    [No Abstract] [Full Text] [Related]

  • 13. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C.
    Rosina P, Girolomoni G.
    Acta Dermatovenerol Croat; 2008 Dec 19; 16(1):35-7. PubMed ID: 18358108
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
    Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group.
    Hepatology; 2001 Aug 19; 34(2):395-403. PubMed ID: 11481625
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.
    Dalmau J, Pimentel CL, Puig L, Peramiquel L, Roé E, Alomar A.
    J Am Acad Dermatol; 2005 Jul 19; 53(1):62-6. PubMed ID: 15965422
    [Abstract] [Full Text] [Related]

  • 16. Pancreatitis induced by pegylated interferon alfa-2b in a patient affected by chronic hepatitis C.
    Cecchi E, Forte P, Cini E, Banchelli G, Ferlito C, Mugelli A.
    Emerg Med Australas; 2004 Jul 19; 16(5-6):473-5. PubMed ID: 15537413
    [Abstract] [Full Text] [Related]

  • 17. Pegylated interferon associated lichen planus at the injection site.
    Ergül B, Koçak E, Akbal E, Köklü S, Astarci HM.
    Acta Gastroenterol Belg; 2011 Dec 19; 74(4):591-2. PubMed ID: 22319976
    [No Abstract] [Full Text] [Related]

  • 18. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.
    Gastroenterology; 2006 Oct 19; 131(4):1040-8. PubMed ID: 17030174
    [Abstract] [Full Text] [Related]

  • 19. [Has hepatitis C become curable by a new pegylated interferon?].
    Trépo C, Merle P.
    Presse Med; 2001 May 19; 30(18):905-8. PubMed ID: 11413851
    [No Abstract] [Full Text] [Related]

  • 20. Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C.
    Altınbas A, Koybasıoglu F, Aktas E, Yılmaz B, Coban S.
    Inflamm Bowel Dis; 2011 Apr 19; 17(4):1050. PubMed ID: 20623698
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.